GLUE
Monte Rosa Therapeutics, Inc.$10.65-0.10 (-0.98%)Prev Close$10.76·MCap$909.4M·P/E—·Vol259.9K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
30
$4.01M
◆
Net Activity
Net Seller
$4.01M
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Monte Rosa Therapeutics, Inc. (GLUE) has been exclusively selling, with 0 insider purchases totaling $0.00 and 30 insider sales totaling $4.01M. The most recent insider transaction was by Bowen Matthew (officer: Principal Accounting Officer), who sold $137.28 worth of shares on Oct 6, 2026. Monte Rosa Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $909.4M.
GLUE Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Bowen Matthew | officer: Principal Accounting Officer | Sell | 13 | $10.56 | $137.28 | 25,891 |
| Jul 17, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 9,500 | $23.18 | $220.2K | 585,038 |
| Jul 16, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 4,351 | $23.38 | $101.7K | 62,371 |
| Jul 7, 2026 | Townson Sharon | officer: Chief Scientific Officer | Sell | 6,000 | $23.31 | $139.8K | 68,245 |
| Jul 1, 2026 | Janku Filip | officer: Chief Medical Officer | Sell | 5,407 | $24.50 | $132.5K | 60,612 |
| Jun 30, 2026 | Janku Filip | officer: Chief Medical Officer | Sell | 6,000 | $22.95 | $137.7K | 59,992 |
| Jun 30, 2026 | Manning Anthony M. | director | Sell | 10,000 | $23.11 | $231.1K | 0Exit |
| Jun 25, 2026 | Janku Filip | officer: Chief Medical Officer | Sell | 41,845 | $21.08 | $882.2K | 59,992-41% |
| Jun 25, 2026 | Townson Sharon | officer: Chief Scientific Officer | Sell | 3,000 | $20.00 | $60.0K | 67,845 |
| Jun 25, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,175 | $20.00 | $43.5K | 62,371 |
| Jun 18, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,176 | $19.00 | $41.3K | 62,371 |
| Jun 18, 2026 | Townson Sharon | officer: Chief Scientific Officer | Sell | 3,000 | $19.00 | $57.0K | 67,845 |
| Jun 2, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 5,466 | $19.44 | $106.3K | 595,006 |
| Jun 1, 2026 | Townson Sharon | officer: Chief Scientific Officer | Sell | 6,000 | $19.87 | $119.2K | 67,845 |
| May 28, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,175 | $20.00 | $43.5K | 62,371 |
| May 26, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,176 | $19.00 | $41.3K | 62,371 |
| May 22, 2026 | Manning Anthony M. | director | Sell | 10,000 | $18.01 | $180.1K | 0Exit |
| May 5, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 5,467 | $18.92 | $103.4K | 600,004 |
| Apr 15, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 8,000 | $17.64 | $141.1K | 605,471 |
| Apr 10, 2026 | Nickson Philip | officer: Chief Business & Legal Officer | Sell | 5,845 | $17.69 | $103.4K | 55,000 |
| Mar 5, 2026 | Dunn Edmund | officer: Principal Accounting Officer | Sell | 139 | $17.96 | $2.5K | 22,554 |
| Mar 2, 2026 | Dunn Edmund | officer: Principal Accounting Officer | Sell | 25,700 | $18.09 | $464.9K | 22,693-53% |
| Feb 24, 2026 | Janku Filip | officer: Chief Medical Officer | Sell | 9,189 | $19.50 | $179.2K | 65,837 |
| Jan 9, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 5,466 | $23.49 | $128.4K | 620,696 |
| Jan 5, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,629 | $15.17 | $39.9K | 62,371 |
| Jan 5, 2026 | Dunn Edmund | Principal Accounting Officer | Sell | 1,039 | $15.17 | $15.8K | 0 |
| Jan 5, 2026 | Janku Filip | officer: Chief Medical Officer | Sell | 3,155 | $15.17 | $47.9K | 75,026 |
| Jan 5, 2026 | Townson Sharon | officer: Chief Scientific Officer | Sell | 3,155 | $15.17 | $47.9K | 67,845 |
| Jan 5, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 10,135 | $15.17 | $153.7K | 624,403 |
| Jan 2, 2026 | Nickson Philip | Chief Business & Legal Officer | Sell | 3,155 | $15.17 | $47.9K | 0 |
| Mar 24, 2025 | Leo Chandra P. | Director | Buy | 10,000 | $5.84 | $58.4K | 0 |
| Oct 30, 2024 | Versant Venture Capital VI, L.P. | Sell | 157,895 | $9.44 | $1.49M | 2,007,948 | |
| Sep 24, 2024 | Versant Venture Capital VI, L.P. | Sell | 1,132,566 | $6.53 | $7.40M1.7% OS | 5,099,336 | |
| Sep 13, 2024 | Versant Venture Capital VI, L.P. | Sell | 567,213 | $6.00 | $3.40M0.9% OS | 6,257,218 | |
| Jul 9, 2024 | Dunn Edmund | Principal Accounting Officer | Sell | 1,610 | $3.83 | $6.2K | 13,944 |
| Jun 5, 2024 | Dunn Edmund | Principal Accounting Officer | Sell | 1,207 | $4.04 | $4.9K | 15,554 |
| Jun 30, 2021 | Bolzon Bradley J PhD | Director | Buy | 157,895 | $19.00 | $3.00M | 2,097,938 |
| Jun 30, 2021 | Cormorant Asset Management, LP | Buy | 600,000 | $19.00 | $11.40M0.9% OS | 3,202,200 | |
| Jun 30, 2021 | Yang Rick | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M1.6% OS | 7,692,298 |
GLUE Insider Buying Activity
The following table shows recent insider purchases of Monte Rosa Therapeutics, Inc. (GLUE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 24, 2025 | Leo Chandra P. | Director | Buy | 10,000 | $5.84 | $58.4K | 0 |
| Jun 30, 2021 | Bolzon Bradley J PhD | Director | Buy | 157,895 | $19.00 | $3.00M | 2,097,938 |
| Jun 30, 2021 | Cormorant Asset Management, LP | Buy | 600,000 | $19.00 | $11.40M0.9% OS | 3,202,200 | |
| Jun 30, 2021 | Yang Rick | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M1.6% OS | 7,692,298 |
GLUE Insider Selling Activity
The following table shows recent insider sales of Monte Rosa Therapeutics, Inc. (GLUE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Bowen Matthew | officer: Principal Accounting Officer | Sell | 13 | $10.56 | $137.28 | 25,891 |
| Jul 17, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 9,500 | $23.18 | $220.2K | 585,038 |
| Jul 16, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 4,351 | $23.38 | $101.7K | 62,371 |
| Jul 7, 2026 | Townson Sharon | officer: Chief Scientific Officer | Sell | 6,000 | $23.31 | $139.8K | 68,245 |
| Jul 1, 2026 | Janku Filip | officer: Chief Medical Officer | Sell | 5,407 | $24.50 | $132.5K | 60,612 |
| Jun 30, 2026 | Janku Filip | officer: Chief Medical Officer | Sell | 6,000 | $22.95 | $137.7K | 59,992 |
| Jun 30, 2026 | Manning Anthony M. | director | Sell | 10,000 | $23.11 | $231.1K | 0Exit |
| Jun 25, 2026 | Janku Filip | officer: Chief Medical Officer | Sell | 41,845 | $21.08 | $882.2K | 59,992-41% |
| Jun 25, 2026 | Townson Sharon | officer: Chief Scientific Officer | Sell | 3,000 | $20.00 | $60.0K | 67,845 |
| Jun 25, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,175 | $20.00 | $43.5K | 62,371 |
| Jun 18, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,176 | $19.00 | $41.3K | 62,371 |
| Jun 18, 2026 | Townson Sharon | officer: Chief Scientific Officer | Sell | 3,000 | $19.00 | $57.0K | 67,845 |
| Jun 2, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 5,466 | $19.44 | $106.3K | 595,006 |
| Jun 1, 2026 | Townson Sharon | officer: Chief Scientific Officer | Sell | 6,000 | $19.87 | $119.2K | 67,845 |
| May 28, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,175 | $20.00 | $43.5K | 62,371 |
| May 26, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,176 | $19.00 | $41.3K | 62,371 |
| May 22, 2026 | Manning Anthony M. | director | Sell | 10,000 | $18.01 | $180.1K | 0Exit |
| May 5, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 5,467 | $18.92 | $103.4K | 600,004 |
| Apr 15, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 8,000 | $17.64 | $141.1K | 605,471 |
| Apr 10, 2026 | Nickson Philip | officer: Chief Business & Legal Officer | Sell | 5,845 | $17.69 | $103.4K | 55,000 |
| Mar 5, 2026 | Dunn Edmund | officer: Principal Accounting Officer | Sell | 139 | $17.96 | $2.5K | 22,554 |
| Mar 2, 2026 | Dunn Edmund | officer: Principal Accounting Officer | Sell | 25,700 | $18.09 | $464.9K | 22,693-53% |
| Feb 24, 2026 | Janku Filip | officer: Chief Medical Officer | Sell | 9,189 | $19.50 | $179.2K | 65,837 |
| Jan 9, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 5,466 | $23.49 | $128.4K | 620,696 |
| Jan 5, 2026 | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,629 | $15.17 | $39.9K | 62,371 |
| Jan 5, 2026 | Dunn Edmund | Principal Accounting Officer | Sell | 1,039 | $15.17 | $15.8K | 0 |
| Jan 5, 2026 | Janku Filip | officer: Chief Medical Officer | Sell | 3,155 | $15.17 | $47.9K | 75,026 |
| Jan 5, 2026 | Townson Sharon | officer: Chief Scientific Officer | Sell | 3,155 | $15.17 | $47.9K | 67,845 |
| Jan 5, 2026 | Warmuth Markus | director, officer: President & CEO | Sell | 10,135 | $15.17 | $153.7K | 624,403 |
| Jan 2, 2026 | Nickson Philip | Chief Business & Legal Officer | Sell | 3,155 | $15.17 | $47.9K | 0 |
| Oct 30, 2024 | Versant Venture Capital VI, L.P. | Sell | 157,895 | $9.44 | $1.49M | 2,007,948 | |
| Sep 24, 2024 | Versant Venture Capital VI, L.P. | Sell | 1,132,566 | $6.53 | $7.40M1.7% OS | 5,099,336 | |
| Sep 13, 2024 | Versant Venture Capital VI, L.P. | Sell | 567,213 | $6.00 | $3.40M0.9% OS | 6,257,218 | |
| Jul 9, 2024 | Dunn Edmund | Principal Accounting Officer | Sell | 1,610 | $3.83 | $6.2K | 13,944 |
| Jun 5, 2024 | Dunn Edmund | Principal Accounting Officer | Sell | 1,207 | $4.04 | $4.9K | 15,554 |
GLUE Insiders
Similar Stocks to GLUE
MRNA
Moderna, Inc.
$225.82+1.80%
$85.50B
REGN
Regeneron Pharmaceuticals, Inc.
$969.36+4.43%
$83.15B
RVMD
Revolution Medicines, Inc.
$190.88-0.20%
$39.42B
ALNY
Alnylam Pharmaceuticals, Inc.
$161.00-2.49%
$30.46B
UTHR
United Therapeutics Corporation
$595.67-0.51%
$25.15B
INCY
Incyte Corporation
$119.31-1.01%
$23.69B
INSM
Insmed Incorporated
$111.22-1.20%
$21.18B
EXEL
Exelixis, Inc.
$71.60+3.14%
$16.64B